NASDAQ · THRX
Healthcare · Biotechnology
$4.07
Up+$0.01 (+0.12%)
Updated Aug 14, 2026, 9:25 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
THRX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning THRX.
THRX research
Company profile and research snapshot.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2023 | Cantor Fitzgerald | Overweight | — |
| Jul 14, 2023 | Wedbush | Outperform | — |
| Jul 14, 2023 | Needham | Hold | — |
| Jul 14, 2023 | HC Wainwright & Co. | Buy | — |
| May 26, 2023 | Needham | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · Dec 29, 2023
Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks Investment Research · Nov 27, 2023
Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.
Benzinga · Nov 14, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 500 points on Tuesday. The Dow traded up 1.60% to 34,885.58 while the NASDAQ rose 2.50% to 14,111.61. The S&P 500 also rose, gaining, 2.06% to 4,502.40. Check This Out: Top 4 Risk Off Stocks You'll Regret Missing In Q4 Leading and Lagging Sectors Real estate shares surged by 5% on Tuesday. In trading on Tuesday, energy shares rose by just 0.5%. Top Headline Home Depot Inc (NYSE: HD) reported better-than-expected third-quarter results. Home Depot reported a FY23 sales decline of 3% year-on-year to $37.71 billion, beating the analyst consensus estimate of $35.66 billion. EPS of $3.81 beat the analyst consensus of $3.58. Equities Trading UP BioCardia, Inc. (NASDAQ: BCDA) shares shot up 168% to $1.0708 after the company announced the FDA approval of its Phase 3 clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. Shares of INVO Bioscience, Inc. (NASDAQ: INVO) got a boost, shooting 27% to $2.05 after the company posted a narrower ...
Benzinga · Nov 14, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday. The Dow traded up 1.42% to 34,833.89 while the NASDAQ rose 2.34% to 14,089.95. The S&P 500 also rose, gaining, 1.93% to 4,496.87. Check This Out: Top 4 Risk Off Stocks You'll Regret Missing In Q4 Leading and Lagging Sectors Real estate shares surged by 4.6% on Tuesday. In trading on Tuesday, energy shares rose by just 0.2%. Top Headline The annual inflation rate in the U.S. eased to 3.2% in October versus 3.7% in both September and August, and compared to market estimates of 3.3%. Equities Trading UP BioCardia, Inc. (NASDAQ: BCDA) shares shot up 206% to $1.22 after the company announced the FDA approval of its Phase 3 clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. Shares of INVO Bioscience, Inc. (NASDAQ: INVO) got a boost, shooting 28% to $2.06 after the company posted a narrower loss for the third quarter. Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning THRX.
No results
No recent SID articles mention THRX.
